A Phase 3 interventional study of Celecoxib in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 11 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing celecoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Celecoxib · Pain.
Among the 22 studies testing celecoxib in Pain, this one is the 11th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 3, and was the 8th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 22 studies testing celecoxib in Pain is open now. The open studies under Pain, anywhere →
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 79 across the 22 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
22 studies in Pain by Viatris Inc.: none open now, none under way, none of them phase 3. Of 22 finished, 18 (82%) have results posted.
Among the 22 studies in Pain by Viatris Inc., this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2009, is one of 10 in phase 3, and was the 9th registered.
Viatris Inc.’s Pain studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing celecoxib in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 22 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate efficacy, safety and tolerability of Celecoxib in patients with posttraumatic pain for the duration of 8 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
"Pain" Pain intensity (Categorical): "Moderate pain" or "Severe pain" Pain intensity (VAS): 45.0 mm or more
"Inflammation" Categorical: "Mild", "Moderate" or "Severe"
Exclusion Criteria:
Drug: Celecoxib
Day 1 * The first dose: Celecoxib 400mg * The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8) - Celecoxib 200mg twice daily
Patient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good")
The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until Final Visit.
Time frame: 8 days
Patient Impressions Within 8 Days Post-first Dose (the Number of Subjects Who Have Rated "Excellent" and "Good")
The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until each time point.
Time frame: 6 hours post first dose and before sleep on Day 1, before sleep on Day 2, Day 4 (Visit 2) and Day 8 (Visit 3)
Pain Intensity (PI) of Pain at Rest (Spontaneous Pain) as Measured by Visual Analog Scale (VAS) Within 8 Days Post-first Dose
The PI of pain at rest (spontaneous pain) was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.
Time frame: Baseline, 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
PI of Pain on Active Movement as Measured by VAS Within 8 Days Post-first Dose
The PI of pain on active movement was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.
Time frame: Baseline, 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
Pain Intensity Differences (PID) in Pain at Rest (Spontaneous Pain) Within 8 Days Post-first Dose
The PID score was obtained by subtracting the PI (by VAS: 0 mm=no pain, 100 mm=worst possible pain) at each time point from the Baseline PI score. Increase in PID scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.
Time frame: Two, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
PID in Pain on Active Movement Within 8 Days Post-first Dose
The PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.
Time frame: 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
Sum of Pain Intensity Differences (SPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose
The SPID was derived according to the following rule: each PID was weighted by the width of time interval between previous and current time points in hours and summed up to 6 hours post-first dose
Time frame: 6 hours
Peak Pain Intensity Difference (PPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose
The PPID was obtained by subtracting the maximum value of pain intensity (PI) at a time point among 2 to 6 hours post first dose from baseline value of PI for each patient.
Time frame: Two, 4 and 6 hours post first dose
Severity of Inflammatory Symptoms (Swelling) Within 8 Days Post-first Dose
The investigator assessed the swelling, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.
Time frame: Baseline, Days 4 (Visit 2) and 8 (Visit 3)
Severity of Inflammatory Symptoms (Redness) Within 8 Days Post-first Dose
The investigator assessed the redness, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.
Time frame: Baseline, Days 4 (Visit 2) and 8 (Visit 3)
Severity of Inflammatory Symptoms (Localized Warmth) Within 8 Days Post First Dose
The investigator assessed the localized warmth, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.
Time frame: Baseline, Days 4 (Visit 2) and 8 (Visit 3)
Withdrawal Due to Lack of Efficacy
The number of subjects who withdrew due to insufficient clinical response was evaluated.
Time frame: 8 days
Summary of Adverse Events
The number of subjects who experienced adverse events (AEs; all-causality and treatment-related) based on safety assessment was summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.
Time frame: 8 days
Subjects were screened at 12 centers in Japan.
| Milestone | Celecoxib |
|---|---|
| Started | 80 |
| Completed | 79 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until Final Visit.
| Participants | Celecoxib |
|---|---|
| Patient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good") | 70 |
The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until each time point.
| Participants | Celecoxib |
|---|---|
| Day 1, 6 hours post first dose (n=80) | 44 |
| Day 1, before sleep (n=80) | 48 |
| Day 2, before sleep (n=80) | 55 |
| Visit 2 (Day 4), (n=80) | 60 |
| Visit 3 (Day 8), (n=68) | 60 |
The PI of pain at rest (spontaneous pain) was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.
| mm | Celecoxib |
|---|---|
| Baseline (n=80) | 59.9 ± 11.4 |
| Day 1, 2 hours post first dose (n=80) | 47.3 ± 19.5 |
| Day 1, 4 hours post first dose (n=80) | 42.5 ± 20.5 |
| Day 1, 6 hours post first dose (n=80) | 40.3 ± 20.9 |
| Day 1, before sleep (n=80) | 38.1 ± 20.0 |
| Day 2, on awakening (n=80) | 34.8 ± 21.5 |
| Day 2, before sleep (n=80) | 29.0 ± 22.0 |
| Day 3, on awakening (n=80) | 24.8 ± 20.0 |
| Day 3, before sleep (n=78) | 21.8 ± 19.1 |
| Day 4, on awakening (n=78) | 18.4 ± 19.6 |
| Day 4, before sleep (n=73) | 17.8 ± 18.9 |
| Day 5, on awakening (n=73) | 15.3 ± 18.0 |
| Day 5, before sleep (n=68) | 15.0 ± 18.7 |
| Day 6, on awakening (n=68) | 12.4 ± 17.2 |
| Day 6, before sleep (n=68) | 11.6 ± 17.3 |
| Day 7, on awakening (n=68) | 11.3 ± 18.1 |
| Day 7, before sleep (n=55) | 9.7 ± 16.2 |
| Day 8, on awakening (n=55) | 8.6 ± 13.3 |
| Visit 3 (Day 8) (n=73) | 7.2 ± 13.0 |
| Final Visit (LOCF, n=80) | 7.3 ± 13.4 |
The PI of pain on active movement was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.
| mm | Celecoxib |
|---|---|
| Baseline (n=79) | 75.5 ± 12.7 |
| Day 1, 2 hours post first dose (n=77) | 61.4 ± 20.2 |
| Day 1, 4 hours post first dose (n=77) | 55.3 ± 21.0 |
| Day 1, 6 hours post first dose (n=77) | 51.5 ± 20.6 |
| Day 1, before sleep (n=77) | 49.3 ± 21.0 |
| Day 2, on awakening (n=77) | 45.5 ± 21.4 |
| Day 2, before sleep (n=77) | 39.7 ± 22.6 |
| Day 3, on awakening (n=77) | 35.5 ± 22.3 |
| Day 3, before sleep (n=75) | 32.4 ± 21.8 |
| Day 4, on awakening (n=75) | 27.2 ± 22.9 |
| Day 4, before sleep (n=70) | 26.4 ± 21.0 |
| Day 5, on awakening (n=70) | 23.5 ± 21.4 |
| Day 5, before sleep (n=66) | 23.2 ± 22.0 |
| Day 6, on awakening (n=66) | 19.2 ± 20.4 |
| Day 6, before sleep (n=66) | 18.2 ± 20.1 |
| Day 7, on awakening (n=66) | 17.1 ± 21.7 |
| Day 7, before sleep (n=55) | 15.5 ± 20.7 |
| Day 8, on awakening (n=55) | 14.3 ± 20.0 |
| Visit 3 (Day8) (n=71) | 12.1 ± 18.7 |
| Final Visit (LOCF, n=78) | 11.8 ± 18.7 |
The PID score was obtained by subtracting the PI (by VAS: 0 mm=no pain, 100 mm=worst possible pain) at each time point from the Baseline PI score. Increase in PID scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.
| mm | Celecoxib |
|---|---|
| Day 1, 2 hours post first dose (n=80) | 12.6 ± 14.8 |
| Day 1, 4 hours post first dose (n=80) | 17.4 ± 16.0 |
| Day 1, 6 hours post first dose (n=80) | 19.6 ± 16.3 |
| Day 1, before sleep (n=80) | 21.8 ± 16.8 |
| Day 2, on awakening (n=80) | 25.1 ± 19.1 |
| Day 2, before sleep (n=80) | 30.9 ± 20.8 |
| Day 3, on awakening (n=80) | 35.1 ± 18.7 |
| Day 3, before sleep (n=78) | 37.9 ± 18.8 |
| Day 4, on awakening (n=78) | 41.3 ± 19.7 |
| Day 4, before sleep (n=73) | 41.8 ± 19.2 |
| Day 5, on awakening (n=73) | 44.3 ± 18.4 |
| Day 5, before sleep (n=68) | 45.4 ± 19.5 |
| Day 6, on awakening (n=68) | 48.0 ± 17.7 |
| Day 6, before sleep (n=68) | 48.8 ± 18.1 |
| Day 7, on awakening (n=68) | 49.2 ± 19.0 |
| Day 7, before sleep (n=55) | 50.2 ± 18.7 |
| Day 8, on awakening (n=55) | 51.3 ± 17.3 |
| Visit 3 (Day 8) (n=73) | 52.4 ± 15.5 |
| Final Visit (LOCF, n=80) | 52.6 ± 15.2 |
The PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.
| mm | Celecoxib |
|---|---|
| Day 1, 2 hours post first dose (n=77) | 14.3 ± 16.6 |
| Day 1, 4 hours post first dose (n=77) | 20.4 ± 17.1 |
| Day 1, 6 hours post first dose (n=77) | 24.3 ± 17.5 |
| Day 1, before sleep (n=77) | 26.5 ± 17.5 |
| Day 2, on awakening (n=77) | 30.3 ± 19.2 |
| Day 2, before sleep (n=77) | 36.1 ± 22.0 |
| Day 3, on awakening (n=77) | 40.2 ± 21.2 |
| Day 3, before sleep (n=75) | 43.2 ± 21.5 |
| Day 4, on awakening (n=75) | 48.5 ± 22.3 |
| Day 4, before sleep (n=70) | 49.5 ± 20.6 |
| Day 5, on awakening (n=70) | 52.5 ± 20.8 |
| Day 5, before sleep (n=66) | 53.5 ± 21.6 |
| Day 6, on awakening (n=66) | 57.5 ± 19.7 |
| Day 6, before sleep (n=66) | 58.4 ± 19.9 |
| Day 7, on awakening (n=66) | 59.6 ± 21.4 |
| Day 7, before sleep (n=55) | 62.1 ± 20.6 |
| Day 8, on awakening (n=55) | 63.3 ± 20.6 |
| Visit 3 (Day 8) (n=71) | 63.6 ± 18.6 |
| Final Visit (LOCF, n=78) | 63.7 ± 18.1 |
The SPID was derived according to the following rule: each PID was weighted by the width of time interval between previous and current time points in hours and summed up to 6 hours post-first dose
| mm | Celecoxib |
|---|---|
| Pain at rest (n=80) | 99.3 (79.9 to 118.7) |
| Pain on active movement (n=77) | 118.2 (96.7 to 139.6) |
The PPID was obtained by subtracting the maximum value of pain intensity (PI) at a time point among 2 to 6 hours post first dose from baseline value of PI for each patient.
| mm | Celecoxib |
|---|---|
| Pain at rest (n=80) | 22.2 (18.6 to 25.8) |
| Pain on active movement (n=77) | 26.7 (22.6 to 30.7) |
The investigator assessed the swelling, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.
| Participants | Celecoxib |
|---|---|
| None at Baseline (n=80) | 0 |
| None at Visit 2 (Day 4) (n=80) | 5 |
| None at Visit 3 (Day 8) (n=68) | 38 |
| None at Final Visit (n=80) | 41 |
| Mild at Baseline (n=80) | 24 |
| Mild at Visit 2 (Day 4) (n=80) | 69 |
| Mild at Visit 3 (Day 8) (n=68) | 26 |
| Mild at Final Visit (n=80) | 35 |
| Moderate at Baseline (n=80) | 48 |
| Moderate at Visit 2 (Day 4) (n=80) | 5 |
| Moderate at Visit 3 (Day 8) (n=68) | 4 |
| Moderate at Final Visit (n=80) | 4 |
| Severe at Baseline (n=80) | 8 |
| Severe at Visit 2 (Day 4) (n=80) | 1 |
| Severe at Visit 3 (Day 8) (n=68) | 0 |
| Severe at Final Visit (n=80) | 0 |
The investigator assessed the redness, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.
| Participants | Celecoxib |
|---|---|
| None at Baseline (n=80) | 16 |
| None at Visit 2 (Day 4) (n=80) | 51 |
| None at Visit 3 (Day 8) (n=68) | 64 |
| None at Final Visit (n=80) | 73 |
| Mild at Baseline (n=80) | 40 |
| Mild at Visit 2 (Day 4) (n=80) | 28 |
| Mild at Visit 3 (Day 8) (n=68) | 4 |
| Mild at Final Visit (n=80) | 7 |
| Moderate at Baseline (n=80) | 19 |
| Moderate at Visit 2 (Day 4) (n=80) | 1 |
| Moderate at Visit 3 (Day 8) (n=68) | 0 |
| Moderate at Final Visit (n=80) | 0 |
| Severe at Baseline (n=80) | 5 |
| Severe at Visit 2 (Day 4) (n=80) | 0 |
| Severe at Visit 3 (Day 8) (n=68) | 0 |
| Severe at Final Visit (n=80) | 0 |
The investigator assessed the localized warmth, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.
| Participants | Celecoxib |
|---|---|
| None at Baseine (n=80) | 8 |
| None at Visit 2 (Day 4) (n=80) | 63 |
| None at Visit 3 (Day 8) (n=68) | 66 |
| None at Final Visit (n=80) | 76 |
| Mild at Baseine (n=80) | 43 |
| Mild at Visit 2 (Day 4) (n=80) | 17 |
| Mild at Visit 3 (Day 8) (n=68) | 2 |
| Mild at Final Visit (n=80) | 4 |
| Moderate at Baseine (n=80) | 23 |
| Moderate at Visit 2 (Day 4) (n=80) | 0 |
| Moderate at Visit 3 (Day 8) (n=68) | 0 |
| Moderate at Final Visit (n=80) | 0 |
| Severe at Baseine (n=80) | 6 |
| Severe at Visit 2 (Day 4) (n=80) | 0 |
| Severe at Visit 3 (Day 8) (n=68) | 0 |
| Severe at Final Visit (n=80) | 0 |
The number of subjects who withdrew due to insufficient clinical response was evaluated.
| Participants | Celecoxib |
|---|---|
| Withdrawal Due to Lack of Efficacy | 0 |
The number of subjects who experienced adverse events (AEs; all-causality and treatment-related) based on safety assessment was summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.
| Participants | Celecoxib |
|---|---|
| AEs: all-causality | 10 |
| AEs: treatment-related | 8 |
| Severe AEs: all-causality | 0 |
| Severe AEs: treatment-realted | 0 |
| Serious AEs: all-causality | 0 |
| Serious AEs: treatment-related | 0 |
| Discontinuation due to all-causality AEs | 1 |
| Discontinuation due to treatment-related AEs | 1 |
| DR/TD due to all-causality AEs | 0 |
| DR/TD due to treatment-related AEs | 0 |
Collected over 8 days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 0/80 (0%) | 10/80 (12.5%) |
| Event | Celecoxib |
|---|---|
| Beta 2 microglobulin urine increasedInvestigations | 5/80 |
| Beta-N-acetyl-D-glucosaminidase increasedInvestigations | 3/80 |
| Blood creatine phosphokinase increasedInvestigations | 3/80 |
| Blood lactate dehydrogenase increasedInvestigations | 2/80 |
| DiarrhoeaGastrointestinal disorders | 1/80 |
| Muscle strainInjury, poisoning and procedural complications | 1/80 |
| Alanine aminotransferase increasedInvestigations | 1/80 |
| Aspartate aminotransferase increasedInvestigations | 1/80 |
| Blood bilirubin increasedInvestigations | 1/80 |
| Urobilin urine presentInvestigations | 1/80 |
| Age, Continuous(Years) | Celecoxib |
|---|---|
| Mean | 37.1 ± 14.4 |
| Sex: Female, Male(Participants) | Celecoxib |
|---|---|
| Female | 39 |
| Male | 41 |
The record gives a start of Sep 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →